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Doxycycline generally alleviates clinical monocytic ehrlichiosis, but its efficacy in the control of monocyto-
tropic ehrlichial pathogens requires further investigation. In this study, Ehrlichia canis was detected in dogs
treated with doxycycline for 14 days and in ticks fed on these dogs, suggesting that treated dogs can remain
reservoirs for E. canis.
Canine monocytic ehrlichiosis (CME) is a cosmopolitan
disease of dogs that is caused by the tick-borne rickettsia,
Ehrlichia canis (20). Ehrlichia spp., like the closely related
genus Anaplasma, are biologically transmitted among verte-
brates by ticks of the family Ixodidae (8), and Rhipicephalus
sanguineus, the “brown dog tick,” is considered the primary
vector of E. canis. In addition to its global importance to
canine health, this vector-pathogen-vertebrate interaction
provides useful transmission and disease models for zoo-
notic tick-borne bacteria, the majority of which naturally
infect dogs.
CME occurs in acute, subclinical, and chronic phases (9, 13,
16, 18, 23). Acute experimental CME often begins approxi-
mately 10 days postinfection (dpi) with E. canis and can involve
anemia, anorexia, ataxia, conjunctivitis, depression, fever, pan-
cytopenia, ocular discharge, and vomiting, with clinical signs
subsiding 20 to 30 dpi and usually followed by a long-term
subclinical phase (1, 3, 12, 21). Long-term mild or severe
chronic phases of CME can also occur, with recurrent clinical
and hematologic signs that include pancytopenia, hemorrhage,
monocytosis, lymphocytosis, and weight loss (9).
The tetracyclines are the drugs of choice for the treatment of
rickettsial diseases. Oral tetracycline and injectable oxytetra-
cycline both are effective treatments for CME (6, 7, 17), and
oral doxycycline was reportedly associated with the lowest in-
cidence of disease recrudescence following treatment (6). Al-
though doxycycline alleviates clinical CME, there are questions
regarding the efficacy of this antibiotic for elimination of E.
canis. Some reports suggested persistence of infection follow-
ing doxycycline regimens of naturally and experimentally
infected dogs during postacute CME (2, 11, 14, 22). Other
reports suggested E. canis clearance after doxycycline treat-
ments of dogs during acute CME (4, 10). Furthermore, the
relevance of E. canis persistence after acute CME is ques-
tioned due to an unsuccessful attempt to infect R. sanguineus
on dogs during subclinical CME (15). However, the utility of
antibiotic treatments to minimize the possibility of E. canis
transmission to invertebrate hosts should be confirmed.
The objective of this study was to determine if doxycycline
treatment would reduce E. canis infection levels sufficiently to
prevent acquisition of the pathogen by R. sanguineus nymphs.
Four Beagle dogs were experimentally infected with E. canis
(Ebony isolate) by tick transmission that was demonstrated in
a previous study (5). All of the dogs tested negative by PCR
and immunofluorescence assays prior to tick feeding, and
transmission was confirmed by seroconversion, mild clinical
signs, and PCR-positive buffy coats after feeding PCR-positive
ticks on these dogs (5). The dog referred to as AXM, which
was not exposed to E. canis, served as a negative control for
feeding cohorts of the ticks used in this study (5). All of the
dogs were cared for in accordance with a protocol on file with
The Ohio State University Institutional Laboratory Animal
Care and Use Committee. Canine blood (5 ml) was collected
with EDTA, and buffy coats were separated as previously de-
scribed (19). Buffy coats and ticks were incubated in protein
digestion buffer and subjected to phenol-chloroform extraction
and ethanol precipitation as reported by Bremer et al. (5),
except the digestion buffer contained 2% sodium dodecyl sul-
fate. PCR assays with primers ECA30-384S and ECA30-583A
were exactly as previously described (5).
Doxycycline hyclate tablets (100 mg) were administered
orally for 14 days (once per day at approximately 10 mg/kg). To
the best of our knowledge, this was the first time these dogs
received this antibiotic. The numbers of days post-tick attach-
ment in the original study to the first day of doxycycline treat-
ment (day 0 in this study) were 55, 76, 83, and 104 for dogs
AHK, AHG, AIP, and AUF, respectively. Semiweekly blood
collections were evaluated with the PCR assay through the
course of treatment. All of the dogs tested PCR positive for E.
canis during doxycycline treatment (Fig. 1), and dogs AIP,
AHG, AUF, and AHK tested PCR positive on 3, 4, 4, and 5
posttreatment sample dates, respectively. Dog AXM, which
was neither exposed to E. canis nor treated with doxycycline,
was PCR negative on each date tested.
For xenodiagnosis, approximately 200 R. sanguineus nymphs
* Corresponding author. Mailing address: Department of Veterinary
Pathobiology, University of Missouri, 210 Connaway Hall, Columbia,
MO 65211. Phone: (573) 882-3148. Fax: (573) 884-5414. E-mail:
stichrw@missouri.edu.
 Published ahead of print on 2 July 2007.
3394
were placed on each dog 7 days after treatment and allowed to
feed to repletion and to molt into adults (5, 19). Cohorts of
these nymphs were fed on untreated dogs and an uninfected
dog as positive and negative controls, respectively. In the first
phase of this experiment, nymphs were fed on dogs AHG and
AHK after treatment. Equivalent numbers (5 of 10) of resul-
tant male ticks tested PCR positive for E. canis from each dog
(Fig. 2A). Nymphs were also fed on dogs AIP and AUF prior
to treatment, and additional nymphs were fed on the same
dogs after the same doxycycline regimen used in the first ex-
periment. Prior to treatment, 4 and 5 of 10 ticks tested PCR
positive for dogs AIP and AUF, respectively, while 10 and 5 of
10 ticks were PCR positive from AIP and AUF, respectively,
after treatment (Fig. 2B). Ticks fed on AXM, the negative
control, were PCR negative (Fig. 2C).
These results confirmed that this doxycycline regimen did
not clear E. canis from these dogs and that R. sanguineus
nymphs acquired infections that persisted through their molt-
ing period. Earlier investigations also suggested persistent in-
fections following doxycycline treatment at similar doses
during subclinical CME. Iqbal and Rikihisa (14) reported re-
isolation of E. canis from three of five experimentally infected
dogs with subclinical CME that were treated for 7 days. Harrus
et al. (11) reported persistent E. canis infection in one of six
dogs after a 42-day regimen. Conversely, other studies sug-
gested clearance of E. canis after doxycycline treatment during
acute CME. Breitschwerdt et al. (4) reported successful clear-
ance of infection from eight of eight dogs with acute experi-
mental CME after 14 days of treatment, while Harrus et al. (10)
reported successful clearance of infection from five of five dogs
after 16 of 60 days of treatment. Taken together, the above-
mentioned investigations suggest that the phase of CME could
affect the efficacy of doxycycline in clearing E. canis infections.
The current study was unique in that ticks were used to
infect and to detect infection of their canine hosts. To our
knowledge, this is the first report of tick acquisition (xeno-
diagnosis) as a means of assessing infection status following
antibiotic treatment. Dogs with postacute, subclinical CME
were used, because our objective was to determine whether
such dogs could be a source of infection for other hosts. In a
clinical setting, treatment of dogs undergoing acute or severe
chronic forms of CME was more likely in the past, but recent
widespread use of serologic tests for exposure to E. canis could
lead to treatment of dogs with subclinical or mild, postacute
CME. Therefore, further work is warranted to evaluate the
efficacy of alternative regimens for elimination of E. canis
during different phases of CME and in hosts experimentally
infected by different means (e.g., needle inoculation and tick
feeding). Vector xenodiagnosis is also a valuable parameter
regarding the efficacy of such regimens to interrupt infectious
cycles of E. canis and, importantly, zoonotic rickettsial patho-
gens that infect dogs.
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FIG. 1. Detection of E. canis in canine blood after doxycycline
treatment. An E. canis-specific PCR assay was used to test buffy coat
samples collected from subclinical experimentally infected dogs
through the course of doxycycline therapy as described in the text. For
each row, no-template reactions (N) served as contamination controls,
template DNA (100 pg) collected from E. canis-infected DH82 cells
served as a positive control (), and the numbers 0 to 28 indicate days
after initiation of doxycycline therapy. The molecular size standard
(M) is a 100-bp ladder (Invitrogen). Doxycycline treatment was initi-
ated after blood collection on day 0 and continued through day 14,
which is indicated by the solid bars. Lanes containing the 200-bp
amplicon (arrowhead) were considered PCR positive. Dog AXM
served as the specific-pathogen-free control, with the numbers 0 to 42
representing days after attachment of uninfected nymphs that were
cohorts of those allowed to acquisition feed on the dogs infected with
E. canis.
FIG. 2. Detection of E. canis in transstadially exposed male R.
sanguineus ticks. Nymphal ticks were allowed to feed to repletion on
infected dogs before or after doxycycline treatment and allowed to
molt into adults, and male ticks were assayed for the presence of E.
canis DNA. No-template reactions (N) served as contamination con-
trols, template DNA (100 pg) collected from E. canis-infected DH82
cells served as a positive control (), and the numbers 1 to 10 repre-
sent individual ticks. The molecular size standard (M) is a 100-bp
ladder. (A) Nymphs were placed on dogs AHG and AHK 7 days after
the treatment ended (day 21). (B) Nymphs were allowed to feed on
dogs AIP and AUF prior to doxycycline therapy (pretreatment), and
more nymphs were placed on the same dogs 7 days after the treatments
ended (posttreatment). (C) Ticks allowed to feed on the uninfected
canine control, AXM.
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